Peptide stability — degradation pathways, storage rules, and the data behind a shelf-life claim

A peptide on the day it ships is not the peptide on the day it is used. Between synthesis and reconstitution, and between reconstitution and the last dose drawn from the vial, the molecule is degrading. How fast depends on the sequence, the formulation, the container, the temperature, and what — if anything — was added as a diluent. A shelf-life claim on a Certificate of Analysis is a statement about how all of those variables have been managed and tested.

This article explains the chemistry by which peptides degrade, the framework that pharmaceutical-grade laboratories use to establish a shelf life, what storage and reconstitution actually accomplish, and how to read the stability information that appears on documentation.

What "stable" means

For a small organic molecule like ibuprofen, stability is mostly a question of whether the active compound is still chemically intact. For a peptide, the molecule can be intact in mass and still inactive in function — disulfide bonds can scramble, residues can racemise from L to D configuration, the secondary structure can collapse irreversibly when concentrated by lyophilisation. A peptide that assays at 99% purity by HPLC may be missing nearly all of its biological activity if the wrong residue has deamidated.

So "stable" is a layered claim. Chemical stability is one layer — the molecule has its expected mass and sequence. Conformational stability is the next — the molecule is in the fold that supports binding. Functional stability is the last — the molecule still does what it is supposed to do. A complete stability program tests all three; most peptide testing in practice covers only the first one, and infers the others.

How peptides degrade

There are roughly six routes by which a peptide can degrade. The relevant ones for any given molecule depend on which residues it contains and which functional groups are exposed.

Hydrolysis. The amide bond linking two amino acids is hydrolysable. Catalysed by acidic or basic pH and accelerated by heat, hydrolysis cleaves the peptide into shorter fragments. The Asp-Pro bond is the most labile under acidic conditions; sequences with adjacent aspartic acid and proline residues will fragment selectively at that point. Hydrolysis is the most important degradation pathway in aqueous solution.

Deamidation. Asparagine and glutamine residues lose their amide group to become aspartic or glutamic acid, often via a cyclic imide intermediate that can also revert to the iso-aspartate isomer. The resulting peptide has a small mass change (~1 Da) and is often hard to detect by routine assay, but the functional consequences can be severe — deamidation at a binding-site residue can abolish activity. The Asn-Gly motif is particularly susceptible. Deamidation accelerates at higher pH and higher temperature.

Oxidation. Methionine, cysteine, tryptophan, tyrosine, and histidine are oxidisable. Methionine oxidises readily to the sulfoxide and then to the sulfone, with mass increases of +16 and +32 Da that are visible by mass spectrometry. Cysteine residues can oxidise to form disulfide bridges (intramolecular or intermolecular), and existing disulfide bridges can scramble between cysteines. Oxidation is driven by dissolved oxygen, trace metals, light, and free radicals; nitrogen overlay and chelating agents during manufacture, and dark storage afterwards, are the standard countermeasures.

Aggregation. Especially for peptides above ~20 residues, intermolecular association can produce dimers, trimers, and higher-order aggregates. Aggregates may be soluble or precipitating. The driving force is hydrophobic surface exposure — the same forces that fold the peptide. Aggregation is concentration-dependent, temperature-dependent, and (importantly) shear-dependent: rough handling of a reconstituted vial can nucleate aggregation. Aggregates change the apparent mass on size-exclusion chromatography and may affect activity.

Racemisation and epimerisation. Under prolonged storage at extreme pH, individual amino acid residues can flip from L to D configuration. The mass is unchanged; HPLC retention may shift only slightly; biological activity is typically lost. Routine COAs do not detect epimerisation unless chiral chromatography or specific enzymatic assays are run.

Cyclisation and chain reactions. N-terminal glutamine residues spontaneously cyclise to pyroglutamic acid with loss of ammonia, masking the N-terminus and shifting the apparent mass. C-terminal disubstitution, succinimide formation at aspartate residues, and Maillard reactions with reducing sugars (if present in formulation) are less common but real pathways.

The relative importance of these pathways depends on the molecule. A short, all-alpha peptide with no methionine, no asparagine adjacent to glycine, and no cysteine will be much more stable than a longer peptide with multiple oxidisable residues and a disulfide bridge.

Lyophilised versus reconstituted

The dominant variable in peptide stability is whether the molecule is in solution or in the dry state. Most degradation pathways — hydrolysis, deamidation, the deprotonation that catalyses oxidation — require water. Removing water by lyophilisation (freeze-drying) effectively pauses these reactions, taking the typical degradation rate from days–weeks to months–years.

A well-lyophilised peptide cake is a porous solid with the original mass of peptide and excipient, the residual moisture typically below 3% by Karl Fischer, and a glass transition temperature high enough that the molecule cannot diffuse meaningfully at storage temperature. For the same molecule, the lyophilised half-life at refrigerator temperature (2–8 °C) is often more than ten times the reconstituted half-life at the same temperature.

This is why peptides are shipped lyophilised. It is also why a vial that has been reconstituted has a much shorter useful life than the same vial unopened. The shelf life printed on a CoA almost always applies to the unopened, lyophilised vial; the in-use period after reconstitution is a separate determination and is often much shorter.

The ICH Q1A framework

Pharmaceutical-grade stability claims rest on a framework laid out in the International Council for Harmonisation Q1A(R2) guideline, titled Stability Testing of New Drug Substances and Products. The guideline defines what evidence is required to support a shelf-life claim and how that evidence must be generated.

In practice, Q1A specifies three categories of stability study:

Long-term (real-time) stability. Samples are stored at the conditions intended for actual storage — typically 5 °C ± 3 °C for refrigerated products or 25 °C ± 2 °C / 60% relative humidity for room-temperature products — and assayed at intervals over the proposed shelf life. The data must extend through the claimed shelf-life period. For a peptide claimed stable for two years at 2–8 °C, the manufacturer must have run real-time stability for at least that long.

Accelerated stability. Samples are stored at elevated temperature and humidity — typically 40 °C ± 2 °C / 75% RH — for six months. The accelerated study probes whether degradation pathways activated at high temperature would compromise the product. A peptide that degrades under accelerated conditions but holds at real-time conditions is acceptable; one that degrades at both is not. Arrhenius extrapolation from accelerated data to real-time stability is permitted only under defined conditions and is not a substitute for real-time data.

Stress stability. Forced-degradation studies at extreme conditions — heat, light, pH, oxidising agent — are used to characterise the molecule's intrinsic degradation pathways and to confirm that the analytical methods can detect the resulting degradants. Stress studies are not a basis for shelf life; they validate the test methods used in the long-term studies.

ICH Q1B covers photostability specifically. ICH Q5C addresses biotechnological and biological products, including the peptides at the larger end of the size range that fall under biologics regulations in some jurisdictions.

A shelf-life claim that is not anchored in this kind of testing is not a shelf-life claim — it is a guess. For a peptide supplied for research use, the absence of formal ICH stability data is not unusual, but a supplier who cannot describe the basis for the expiry date is one whose expiry date is informationally empty.

What a shelf-life claim looks like with evidence

A complete stability claim on a peptide CoA, when documented properly, would specify:

The storage conditions assumed (e.g. "2–8 °C, protected from light")
The claimed shelf life under those conditions (e.g. "24 months from manufacture")
The container–closure system tested (e.g. "type I glass vial, butyl rubber stopper, aluminium overseal")
The stability-indicating methods used (HPLC for purity, mass spec for identity and oxidation, sometimes additional methods for specific pathways)
The acceptance criteria — what limits define "still passing" — for each method
The duration of real-time data supporting the claim

Most peptide CoAs in the research-grade market list only the expiry date and storage temperature. The chain of evidence behind that date is rarely disclosed. Buyers wanting confidence in shelf life can request the stability summary; reputable suppliers can provide one, even if redacted.

Storage temperature, in practice

For lyophilised peptides, the storage-temperature hierarchy runs:

−80 °C (deep freezer): Maximum stability. Used by laboratories planning to hold reference materials for years. The container must be properly sealed to prevent moisture ingress on warming.
−20 °C (standard freezer): Common for working stocks of lyophilised material. Repeated freeze–thaw cycles of lyophilised material are not generally problematic (unlike for reconstituted material), but should be minimised because each warming cycle exposes the cake to atmospheric moisture if the seal is broken.
2–8 °C (refrigerator): Adequate for many peptides over months-to-years timeframes. The typical "ship cold, store cold" range.
Ambient (15–25 °C): Suitable for short-term holding but generally not for long-term storage of high-value peptides. Some peptides are formulated specifically for room-temperature stability.

For reconstituted peptides, the temperature hierarchy compresses dramatically. A reconstituted peptide at 2–8 °C may be usable for days to weeks; at room temperature, hours to days; the longer end of those ranges depends on whether the diluent contains a preservative (such as benzyl alcohol in bacteriostatic water) and whether the molecule is one of the more stable sequences.

Reconstitution — diluent grade and technique

The choice of diluent is part of the stability question.

Water for injection (WFI) is the pharmaceutical reference grade — sterile, pyrogen-free, no preservatives. A vial reconstituted with WFI offers the cleanest chemistry but has the shortest in-use period because there is no antimicrobial protection once the seal is broken.

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative. The presence of benzyl alcohol extends the in-use period — typically 28 days at 2–8 °C, per USP <797> limits for multi-dose vials — by suppressing microbial growth. Benzyl alcohol does not protect against chemical degradation of the peptide itself, only against contamination. For peptides intolerant of benzyl alcohol or for use cases requiring preservative-free formulation, BWFI is contraindicated.

Sodium chloride 0.9% (normal saline) is sometimes used for peptides where isotonicity is important. Plain saline is sterile but not bacteriostatic; the in-use period after opening is short.

Acetic acid solutions (typically 0.1% or 1%) are used for peptides that aggregate at neutral pH. Acidic diluents stabilise some sequences and destabilise others; the formulation work that determines which is appropriate is part of the manufacturer's development data.

The mechanics of reconstitution matter as much as the diluent. The diluent should be added to the vial slowly, against the inside wall of the vial, not directly onto the lyophilised cake. The vial should be gently swirled — not shaken vigorously — until the cake is fully dissolved. Foaming is a sign that the peptide is being subjected to shear stress at the air–water interface, which can nucleate aggregation. A reconstituted vial that looks cloudy, contains visible particles, or has a precipitate has aggregated peptide and should not be used.

Reading stability information on a Certificate of Analysis

The stability section of a CoA, when present, may include:

Manufacture date. The date of the final synthesis or final processing step.
Expiry date or re-test date. The date past which the lot is no longer warranted to meet specifications. A re-test date implies that testing is required to extend usability; an expiry date implies the lot is to be retired.
Storage conditions. The temperature range under which the expiry date applies.
In-use stability. Some manufacturers provide a stability period for the reconstituted vial under specified conditions; many do not.
Stability-indicating methods. Occasionally cited; usually refers to HPLC with mass spectrometric confirmation.

A CoA whose only stability information is "store frozen, use by [date]" tells the buyer the supplier wants the material stored frozen and used by a date. It does not tell the buyer what data supports the date. For a research-use peptide, this minimal disclosure is common; for a peptide intended for any work where stability matters operationally — reference standards, longitudinal studies, comparison between lots — the buyer should ask for the underlying stability summary.

Common practical errors

A handful of practical mistakes account for most of the stability failures observed in the field:

Reconstituting with the wrong diluent — using bacteriostatic water where the peptide is incompatible with benzyl alcohol, or using non-sterile water and contaminating a multi-dose vial.
Vigorous shaking instead of gentle swirling — nucleating aggregation through air–water interface shear.
Storing reconstituted material at room temperature — the in-use shelf life of a reconstituted vial at room temperature is short for almost all peptides.
Repeated freeze–thaw of reconstituted solution — every cycle promotes aggregation and degradation. For long storage of a reconstituted aliquot, single-use frozen subdivisions are preferred to repeatedly thawing one stock.
Holding lyophilised vials in the refrigerator door — the temperature in the door swings with every opening, exceeding the 2–8 °C specification more often than in the body of the refrigerator.
Ignoring the manufacture date — a peptide with a 24-month expiry is more degraded near the expiry date than at manufacture. Where stability is critical, fresh lots should be preferred.

None of these errors will produce a result on a Certificate of Analysis. They will produce a vial that performs worse than the CoA predicts.

Where stability connects to the rest of the testing

A Certificate of Analysis sets the starting condition of the vial. Stability sets the trajectory from that starting condition over time. The chromatographic and mass-spectrometric methods that establish purity at release are the same methods used in stability studies to track degradation — see HPLC for peptides for the chromatography side and how to read a peptide CoA for the document those methods feed into.

The laboratories that perform stability studies under ICH conditions are, in most cases, the same laboratories that perform release testing. The competence framework — ISO 17025 accreditation — applies equally. A laboratory accredited for purity testing of synthetic peptides under defined matrix and concentration ranges is, by extension, equipped to perform stability testing on those same peptides; the same methods are simply applied to samples drawn at intervals over time.

The independent laboratories that buyers might commission for confirmatory testing are mapped in the third-party peptide testing landscape — many of those facilities offer stability testing as a discrete service for buyers who want to verify a supplier's expiry-date claim against an independent measurement.